The primary role of the COVID-19 Evidence team is to support the use of evidence within UKHSA’s COVID-19 response. This is achieved by identification of rapid reviews on relevant topics (both published and ongoing), production of evidence summaries and rapid reviews, and by identification of evidence gaps.
The COVID-19 Evidence team consists of a number of core members including a cell lead, reviewers, an information scientist and administration support, plus a flexible pool of reviewers and topic experts.
Rapid review process
We produce the following outputs:
Scoping search – a search of COVID-19 review repositories and additional sources [see current list], in order to quickly identify published or ongoing relevant reviews.
Scoping summary – a brief summary (1-2 pages) of mainly review-level evidence, found from the above scoping search, with the aim of understanding the amount and quality of review-level evidence available on a topic. A scoping summary usually involves an appraisal of any reviews identified, using AMSTAR 2. Scoping summaries end with options for further work, including producing an evidence summary, conducting a new rapid review (or updating an existing review) or no further action. Note: a scoping summary is produced for every question unless a new review is fast-tracked due to importance.
Evidence summary – a detailed summary and quality appraisal of one or more relevant reviews that answers a specific question, or makes a significant contribution towards answering a question. Note: an evidence summary is produced if a relevant review of acceptable quality is identified, and aims to avoid duplication of effort by summarising existing reviews instead of replicating a similar review. Occasionally, an evidence summary will be produced using a lower quality review due to time constraints.
Rapid review – our rapid reviews adopt systematic review methods, with parts of the review process simplified, to allow a product to be delivered in a shorter timescale. They involve a systematic search, screening, data extraction, critical appraisal and synthesis of the relevant evidence, using a protocol, in order to answer a specific question. Timeframes to produce these vary from 3 days to 2 weeks. The search strategy and study selection methods for each of our rapid reviews are included in the documents in the table of publications below. Note: a rapid review may be produced if no existing relevant review of acceptable quality is found – if a similar external review is currently underway (e.g. registered in Prospero), the completion date and results of this will be assessed first.
Table of publications showing review questions, current stage of review and last search date
New reviews will be added to the table as soon as they are accepted by the COVID-19 Evidence team.
UKHSA’s rapid reviews aim to provide the best available evidence to decision makers in a timely and accessible way, based on published peer-reviewed scientific papers, unpublished reports and papers on pre-print servers. Please note that the reviews: i) use accelerated methods and may not be representative of the whole body of evidence publicly available; ii) have undergone an internal, but not independent, peer review; and iii) are only valid as of the date stated on the review.
In the event that this review is shared externally, please note additionally, to the greatest extent possible under any applicable law, that UKHSA accepts no liability for any claim, loss or damage arising out of, or connected with the use of, this review by the recipient and/or any third party including that arising or resulting from any reliance placed on, or any conclusions drawn from, the review.
Contact us: Covid19Evidence@phe.gov.uk